Letters To The Editor
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL)
Zhong et al. (1) characterize PRN694, a dual inhibitor of ITK and resting lymphocyte kinase (RLK). They demonstrate activity against T-cell receptor (TCR) signaling in T-PLL and suggest a therapeutic application. However, an actual TCR dependence of T-PLL is not established (2), and cytotoxic consequences of inhibited kinase activation in T-PLL cells by PRN694 (1) or various other ITK inhibitors (3) are not reported.
